Personalis, Inc. (PSNL)
Price:
8.61 USD
( - -0.07 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
OPKO Health, Inc.
VALUE SCORE:
6
2nd position
GRAIL, Inc.
VALUE SCORE:
9
The best
Medpace Holdings, Inc.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
NEWS
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-09-15 17:35:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis' new Senior Vice President, Chief Information Officer under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awa.
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
businesswire.com
2025-09-10 16:05:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale Cancer Center for a clinical trial titled “A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE),” a novel ctDNA-guided study aimed at improving outcomes in patients w.
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
zacks.com
2025-08-13 10:36:05The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
zacks.com
2025-08-12 10:35:23Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
zacks.com
2025-08-08 13:01:10Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
2025-08-06 08:11:55U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
Personalis (PSNL) Q2 Revenue Falls 24%
fool.com
2025-08-06 05:14:08Personalis (PSNL) Q2 Revenue Falls 24%
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-05 22:49:21Personalis, Inc. (NASDAQ:PSNL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Aaron L. Tachibana - CFO & COO Christopher M.
Personalis Reports Second Quarter 2025 Financial Results
businesswire.com
2025-08-05 16:01:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its “Win-in-MRD” strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal®.
Personalis to Announce Second Quarter 2025 Financial Results
businesswire.com
2025-07-22 16:01:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers.
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-07-18 16:00:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis' new Vice President, Corporate Controller under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individual.
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
businesswire.com
2025-07-09 16:00:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung an.
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
zacks.com
2025-07-03 08:11:04Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
zacks.com
2025-06-17 11:41:04Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
No data to display
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-09-15 17:35:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on September 15, 2025, a non-qualified stock option to purchase an aggregate of 440,000 shares of its common stock to Personalis' new Senior Vice President, Chief Information Officer under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awa.
CATE Clinical Trial Launched to Demonstrate the Clinical Utility of ctDNA-Guided Treatment in Breast Cancer Using the Ultrasensitive NeXT Personal Test
businesswire.com
2025-09-10 16:05:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced its collaboration with a leading breast cancer team from Yale Cancer Center for a clinical trial titled “A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE),” a novel ctDNA-guided study aimed at improving outcomes in patients w.
Down 27.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Personalis (PSNL)
zacks.com
2025-08-13 10:36:05The heavy selling pressure might have exhausted for Personalis (PSNL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
After Plunging 30.5% in 4 Weeks, Here's Why the Trend Might Reverse for Personalis (PSNL)
zacks.com
2025-08-12 10:35:23Personalis (PSNL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
All You Need to Know About Personalis (PSNL) Rating Upgrade to Buy
zacks.com
2025-08-08 13:01:10Personalis (PSNL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Super Micro Computer Posts Downbeat Q4 Results, Joins Personalis, Snap And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
benzinga.com
2025-08-06 08:11:55U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
Personalis (PSNL) Q2 Revenue Falls 24%
fool.com
2025-08-06 05:14:08Personalis (PSNL) Q2 Revenue Falls 24%
Personalis, Inc. (PSNL) Q2 2025 Earnings Call Transcript
seekingalpha.com
2025-08-05 22:49:21Personalis, Inc. (NASDAQ:PSNL ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Aaron L. Tachibana - CFO & COO Christopher M.
Personalis Reports Second Quarter 2025 Financial Results
businesswire.com
2025-08-05 16:01:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its “Win-in-MRD” strategy: Second Quarter 2025 and Recent Business Highlights Clinical Adoption Acceleration: Delivered 3,478 clinical tests in the second quarter, a 59% sequential increase over Q1 2025, demonstrating accelerating physician adoption of the NeXT Personal®.
Personalis to Announce Second Quarter 2025 Financial Results
businesswire.com
2025-07-22 16:01:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers.
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-07-18 16:00:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis' new Vice President, Corporate Controller under Personalis' 2020 Inducement Plan. The 2020 Inducement Plan is used exclusively for the grant of equity awards to individual.
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients
businesswire.com
2025-07-09 16:00:00FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung an.
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
zacks.com
2025-07-03 08:11:04Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Personalis (PSNL) Soars 7.3%: Is Further Upside Left in the Stock?
zacks.com
2025-06-17 11:41:04Personalis (PSNL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.